Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Nealon who started this subject	9/24/2003 3:25:22 AM
From: nigel bates	Read Replies (1) of 123

Celltech Group PLC Announces Merck Extends Development Period For PDE4 Collaboration With Celltech SLOUGH, UK, Sept. 24, 2003 (PRIMEZONE) -- Celltech Group plc (London:CCH.L - News) (NYSE:CLL - News) announces that Merck & Co., Inc. (NYSE:MRK - News) (Other OTC:MCKIF.PK - News) has exercised its option to extend the Development Period regarding its phosphodiesterase-4 (PDE4) inhibitors collaboration with Celltech. The exercise of this option enables Merck to maintain exclusive access to Celltech's PDE4 intellectual property estate, which was licensed by Celltech to Merck as part of their collaboration in 1994. Pursuant to this, Merck will shortly make an undisclosed milestone payment to Celltech. Merck is currently undertaking clinical development of PDE4 inhibitors for respiratory diseases. Celltech Group plc (LSE: CCH; NYSE: CLL) is one of Europe's largest biotechnology companies, with an innovative development pipeline and a profitable, cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering. More details can be found at celltechgroup.com...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next